Novo Nordisk: Approval in the UK! With the Wegovy Pill to a USD 3.25 Billion Sales Opportunity?

After a turbulent year 2025, marked by profit warnings and strategic realignments, Novo Nordisk seems to have finally achieved a turnaround in 2026. This optimism is driven by the successful market launch of the Wegovy pill in the USA. With availability in over 70,000 pharmacies, including CVS, Costco, and Amazon Pharmacy, the Danish company demonstrates a logistical dominance that puts competitor Eli Lilly under noticeable pressure. Additionally, on January 16, 2026, a UK approval of Wegovy in the 7.2 mg dosage allows for three injections of 2.4...